image credit- shutterstock
Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Adalvo Limited in the European and Brazilian markets for exclusive rights to the commercialisation of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative treatment of post-operative inflammation and pain following ocular surgery.
The licensing agreement with Adalvo includes upfront payment, sales milestones, and profit sharing, with additional considerations throughout the term of the agreement.
The European ophthalmology market reached $16 billion in 2024, with Germany and the UK leading as the largest markets. Cataract surgery is among the most common procedures performed in EU hospitals, driving demand for effective post-operative treatments. Looking ahead, the ocular surgery segment is projected to grow to $38 billion by 2032.
